Gautam Sanyal received his Ph.D. in physical chemistry from the <em>University of Virginia. </em>After spending a few years in academic research and teaching positions at <em>University of Florida, Mayo Clinic </em>and <em>Hamilton College</em>, Gautam moved in 1989 to <em>Merck Research laboratories </em>at WestPoint, PA. He was among the first group of scientists that built protein and vaccine formulation capabilities at <em>Merck</em>. Gautam played critical roles in delivering several candidate vaccine antigens and therapeutic proteins into clinical trials, some of which led to products such as <em>Gardasil </em>for prophylaxis against human papilloma virus. After nine productive and stimulating <em>Merck </em>years, Gautam joined <em>Astra Research Center Boston </em>as Head of Formulation and Analytical Research. Following the merger of <em>Astra </em>and <em>Zeneca</em>, he took on Head of Biochemistry and Protein Biophysics roles at <em>AstraZeneca Infection</em>, and was involved in discovery of novel antibacterials. Subsequently, at <em>MedImmune</em>, Gautam led analytics development for viruses and vaccines in pre-clinical and clinical phases. His CMC project responsibilities included an RSV vaccine through phase I and II clinical trials. In addition, Gautam led building of an analytical platform for development of oncolytic viruses for cancer immunotherapy. He has extensively published research papers and review articles on characterization, formulation and assay development for proteins and vaccines.

Gautam retired from industry in 2017 and founded <em>Vaccine Analytics, LLC, </em>to work as an independent consultant and is also a subject matter expert for Global Health Organizations. In addition, he is a member in the board of Directors of IABS, USA.